Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Langhans, Bettina ^a   Nischalke, Hans Dieter ^a   Arndt, Simone ^a   Braunschweiger, Ingrid ^a   Nattermann, Jacob ^a   Sauerbruch, Tilman ^a   Spengler, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; RIBAVIRIN;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE CLONE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; REGULATORY T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ADULT; AGED; ANTIVIRAL AGENTS; CELL PROLIFERATION; CLONE CELLS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; RIBAVIRIN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS;

HEPATITIS C VIRUS;

EID: 84864406559     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042094     Document Type: Article

References (35)

1. Shepard CW, Finelli L, Alter MJ, ((2005)) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:: 558--567.
2. Aghemo A, Rumi MG, Colombo M, ((2009)) Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect Ther 7:: 925--935.
3. Lau JYN, Tam RC, Liang TJ, Hong Z, ((2002)) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35:: 1002--1009.
4. Spengler U, Nattermann J, ((2007)) Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci 112:: 141--155.
5. Barnes E, Harcourt G, Brown D, Lucas M, Phillips R, et al. ((2002)) The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 36:: 743--754.
6. Rahman F, Heller T, Sobao Y, Mizukoshi E, Nascimbeni M, et al. ((2004)) Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology40 (1):: 87--97.
7. Reiser M, Marousis CG, Nelson DR, Lauer G, González-Peralta RP, et al. ((1997)) Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J Hepatol 26:: 471--478.
8. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM, ((1996)) Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 24:: 6--9.
9. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, et al. ((2000)) Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118:: 346--355.
10. Fang SH, Lai MY, Hwang LH, Yang PM, Chen PJ, et al. ((2001)) Ribavirin enhances interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha. Biomed Sci 8:: 484--491.
11. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, et al. ((1996)) Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 25:: 591--598.
12. Hultgren C, Milich DR, Weiland O, Sällberg M, ((1998)) The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. Gen Virol 79:: 2381--2391.
13. Fang SH, Hwang LH, Chen DS, Chiang BL, ((2000)) Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 33:: 791--798.
14. Tam RC, Pai B, Bard J, Lim C, Averett DR, et al. ((1999)) Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 30:: 376--382.
15. Rigopoulou EI, Abbott WG, Williams R, Naoumov NV, ((2007)) Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Res 75:: 36--42.
16. Manigold T, Racanelli V, ((2007)) T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis 7:: 804--813.
17. Dolganiuc A, Szabo G, ((2008)) T cells with regulatory activity in hepatitis C virus infection: what we know and what we don't. J Leukoc Biol 84:: 614--622.
18. Alatrakchi N, Koziel M, ((2009)) Regulatory T cells and viral liver disease. J Viral Hepat 16:: 223--229.
19. Langhans B, Braunschweiger I, Arndt, S Schulte W, Satoguina J, et al. ((2010)) Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. Clin Sci 119:: 97--109.
20. Golding A, Rosen A, Petri M, Akhter E, Andrade F, ((2010)) Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology 131:: 107--117.
21. Khakoo S, Glue P, Grellier L, Wells B, Bell A, et al. ((1998)) Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 46:: 563--570.
22. Slavenburg S, Huntjens-Fleuren HWHA, Dofferhoff TSN, Richter C, Koopmans PP, et al. ((2011)) Ribavirin plasma concentration measurements in patients with hepatitis C. Early ribavirin concentrations predict steady-state concentrations. Ther Drug Monit 33:: 40--44.
23. Nicot F, Legrand-Abravanel F, Lafont T, Dubois M, Sauné K, et al. ((2008)) Serum concentrations of ribavirin and pegylated interferon and virla responses in patients infected with HIV and HCV. J Med Virol 80:: 1523--1529.
24. Mori R, Wang Q, Danenberg KD, Pinski JK, Danenberg PV, ((2008)) Both beta-actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer. Prostate 68:: 1555--1560.
25. Weglarz L, Molin I, Orchel A, Parfiniewicz B, Dzierzewicz Z, ((2006)) Quantitative analysis of the level of p53 and p21(WAF1) mRNA in human colon cancer HT-29 cells treated with inositol hexaphosphate. Acta Biochim Pol 53:: 349--356.
26. Clark V, Nelson DR, ((2012)) The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Liver Int Feb 32 Suppl 1: 103--7.
27. Feld JJ, Lutchman GA, Heller T, Hara K, Pfeiffer JK, et al. ((2010)) Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 139:: 154--62.e4.
28. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, et al. ((2011)) Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53:: 32--41.
29. Stevenson NJ, Murphy AG, Bourke NM, Keogh CA, Hegarty JE, et al. ((2011)) Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PLoS One 6(11):: e27866--e27866.
30. Burton JR Jr, Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, et al. ((2008)) Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol 49:: 329--338.
31. Akiyama M, Ichikawa T, Miyaaki H, Motoyoshi Y, Takeshita S, et al. ((2010)) Relationship between regulatory T cells and the combination of pegylated interferon and ribavirin for the treatment of chronic hepatitis type C. Intervirology 53:: 154--160.
32. Claassen MA, de Knegt RJ, Janssen HL, Boonstra A, ((2011)) Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans. J Virol 85:: 5323--5330.
33. Westin J, Hellstrand K, Dhillon AP, Lagging M, ((2011)) DITTO-HCV Study Group ((2011)) Are FoxP3(+) cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C? J Viral Hepat 18:: 149--151.
34. Brenndörfer ED, Brass A, Söderholm J, Frelin L, Bode JG, Sählber M (2012) The HCV NS3/4A-mediated impairment of the hepatic antiviral immune response is reversed by protease inhibition or ribavirin in vivo. EASL: abstract #1234.
35. Atsukawa M, Nakatsuka K, Kobayashi T, Shimizu M, Tamura H, et al. ((2012)) Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance. J Gastroenterol Hepatol 27:: 823--831.